Pan-her antibody composition

Abstract

The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.

1 - 50 . (canceled) 
     
     
         51 . A method of treating a human having a disorder characterized by EGFR, HER2, or HER3 dependency, comprising administering to the patient a pharmaceutical antibody composition comprising:
 a) a humanized anti-EGFR antibody comprising the heavy and light chain CDR1-3 in:
 i) SEQ ID NOs: 18 and 20, respectively, 
 ii) SEQ ID NOs: 22 and 24, respectively, or 
 iii) SEQ ID NOs: 14 and 16, respectively; 
   b) a humanized anti-HER2 antibody comprising the heavy and light chain CDR1-3 in:
 i) SEQ ID NOs: 30 and 32, respectively, 
 ii) SEQ ID NOs: 34 and 36, respectively, 
 iii) SEQ ID NOs: 38 and 40, respectively, or 
 iv) SEQ ID NOs: 42 and 44, respectively; and 
   c) a humanized anti-HER3 antibody comprising the heavy and light chain CDR1-3 in:
 i) SEQ ID NOs: 50 and 52, respectively, or 
 ii) SEQ ID NOs: 54 and 56, respectively. 
   
     
     
         52 . The method of  claim 51 , wherein said composition comprises:
 a) a first humanized anti-EGFR antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 18 and 20, respectively; and a second humanized anti-EGFR antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 22 and 24, respectively;   b) a first humanized anti-HER2 antibody comprising the heavy and light chain CDR1-CDR3 in SEQ ID NOs: 30 and 32, respectively; and a second humanized anti-HER2 antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 38 and 40, respectively; and   c) a first humanized anti-HER3 antibody comprising the heavy and light chain CDR1-CDR3 in SEQ ID NOs: 50 and 52, respectively; and a second humanized anti-HER3 antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 54 and 56, respectively.   
     
     
         53 . The method of  claim 51 , wherein said composition comprises:
 a) a first humanized anti-EGFR antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 18 and 20, respectively; and a second humanized anti-EGFR antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 22 and 24, respectively;   b) a first humanized anti-HER2 antibody comprising the heavy and light chain CDR1-CDR3 in SEQ ID NOs: 34 and 36, respectively; and a second humanized anti-HER2 antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 42 and 44, respectively; and   c) a first humanized anti-HER3 antibody comprising the heavy and light chain CDR1-CDR3 in SEQ ID NOs: 50 and 52, respectively; and a second humanized anti-HER3 antibody comprising the heavy and light chain CDR1-3 in SEQ ID NOs: 54 and 56, respectively.   
     
     
         54 . The method of  claim 51  or  52 , wherein the disorder is cancer. 
     
     
         55 . The method of  claim 54 , wherein the cancer is breast cancer, lung cancer, head and neck cancer, colorectal cancer, or pancreatic cancer, 
     
     
         56 . The method of  claim 54 , wherein said cancer has acquired resistance to treatment with an anti-EGFR, anti-HER2 or anti-HER3 antibody, or a tyrosine kinase inhibitor. 
     
     
         57 . The method of  claim 54 , wherein the patient is treated with at least one additional therapeutic treatment. 
     
     
         58 . The method of  claim 57 , wherein the at least one additional therapeutic treatment is chemotherapy. 
     
     
         59 . The method of  claim 57 , wherein the at least one additional therapeutic treatment is radiation.